MTOR and cholangiocarcinoma: Medicarpin-associated targets were significantly enriched in oncogenic pathways critical to CCA progression, including PI3K/AKT/mTOR, MAPK, apoptosis, and cell-cycle regulation, underscoring its capacity to simultaneously influence multiple signaling pathways that promote tumour proliferation and therapeutic resistance.